TriangleNCT01282424 · OUTCOME
Change in Health-Related Quality of Life Using the Functional Assessment of Cancer Therapy: Lymphoma Subscale (FACT-LymS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- units on a scale
- Interval / dispersion
- Standard Deviation
- Time frame
- Baseline to End of Treatment (up to 81 months)
What was measured
Change in health-related quality of life events were reported by participants using the Functional Assessment of Cancer Therapy: Lymphoma Subscale (FACT-LymS) assessment tool. Results are presented as the mean (SD) best change from baseline. The best change from baseline was defined as the highest change score (improvement) after baseline. The FACT-LymS is on a scale from 0-60, with higher scores associated with a better quality of life. It incorporates values from 15 questions, each rated 0-4, related to study indications.
Analysis population: Participants in the ITT Analysis Set with available data were analyzed.
Groups in this outcome
Idelalisib
Idelalisib 150 mg tablet administered orally twice daily until tumor progression or development of unacceptable toxicity.
| Group | Source count |
|---|---|
| Idelalisib | 113 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Idelalisib | 10.3 | 17.08 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 17.08
- value
- 10.3
- denoms
- counts
- group Id
- OG000
- value
- 113
- units
- Participants
- description
- Change in health-related quality of life events were reported by participants using the Functional Assessment of Cancer Therapy: Lymphoma Subscale (FACT-LymS) assessment tool. Results are presented as the mean (SD) best change from baseline. The best change from baseline was defined as the highest change score (improvement) after baseline. The FACT-LymS is on a scale from 0-60, with higher scores associated with a better quality of life. It incorporates values from 15 questions, each rated 0-4, related to study indications.
- dispersion Type
- Standard Deviation
- groups
- description
- Idelalisib 150 mg tablet administered orally twice daily until tumor progression or development of unacceptable toxicity.
- id
- OG000
- title
- Idelalisib
- param Type
- MEAN
- population Description
- Participants in the ITT Analysis Set with available data were analyzed.
- reporting Status
- POSTED
- time Frame
- Baseline to End of Treatment (up to 81 months)
- title
- Change in Health-Related Quality of Life Using the Functional Assessment of Cancer Therapy: Lymphoma Subscale (FACT-LymS)
- type
- SECONDARY
- unit Of Measure
- units on a scale
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice